Background: C9, a newly in silico-designed inhibitor of microtubule dynamics induces G 2 /M arrest culminating in apoptosis. Dichloroacetate (DCA) inhibits pyruvate dehydrogenase kinase, an enzyme that promotes pyruvate entry into mitochondria. The use of antitumor drugs targeting different cancer features can be a more effective way to overcome drug resistance.
Introduction
Increased understanding of the evolutionary origins of cancer has helped researchers comprehend how resistance to anticancer treatment emerges [1] . Hanahan and Weinberg [3] .
Treatment of cancer with combination therapies targeting at least two different pathways is preferable [4] . This can be achieved by treating cancer with different types of chemotherapeutic agents or one agent that is capable of targeting numerous signalling pathways.
(OXPHOS) These characteristics separate cancer cells from normal functioning cells and can be seen as
The combination of antimitotic compounds together with compounds that can target the dysregulated metabolism of many therapeutic promise in patients with advanced solid tumors [6] . Tagg et al. [7] demonstrated in vivo.
in silico designed by our group . C9 has improved bioavailability because of the ability of the sulphamoyl moiety to to circumvent liver metabolism [11] to improve the antimitotic activity of estradiol analogues and dehydration at positions [13] .
[14].
cancer growth .
This allows for the translocation of from the mitochondrial c in lung cancer cells [18] reported that this small molecule has the ability to induce apoptosis in vitro and in vivo .
(in vitro in vivo) through signalling that involves the inhibition . glycolytic inhibitor and other one an antimitotic compound. C9 is an antimitotic compound which disrupts tubulin polymerization in actively dividing cells. Treatment of C9 on cells ROS level and intrinsic apoptotic cell death by forcing cancer cells to utilize the mitochondria for energy production . It is thus possible that combination treatment of cells with to elucidate the mechanisms of action of in silico cancer.
towards the breast carcinoma cells [9] synergism .
In the pilot cell death. It was proposed that the selectivity of the combination treatment is associated breast cells. , P P the same treatment. formation and fragmentation of genomic material. .
Materials and Methods

Compounds and reagents O
C9 is an
Caspase 7 activity was used as a positive control for apoptosis induction and to ensure the correct protocol was 
